MCK icon

McKesson

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 26.5%
Negative

Positive
Zacks Investment Research
13 hours ago
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Neutral
Zacks Investment Research
yesterday
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
Negative
Barrons
yesterday
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Those looking to buy stocks right now should look for the ones that aren't correlated to the artificial intelligence trade.
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Positive
Zacks Investment Research
yesterday
Here's Why McKesson (MCK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why McKesson (MCK) is a Strong Momentum Stock
Positive
Seeking Alpha
4 days ago
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy
McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM Vision, Core Ventures) and organizational restructuring position MCK for sustained growth in oncology, multispecialty, and technology-enabled segments. Q1 FY26 results showed strong revenue growth, robust cash flow guidance, and raised long-term EPS targets, reflecting confidence in durable earnings momentum.
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy
Positive
Seeking Alpha
4 days ago
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity
McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology Solutions. MCK's upgraded long-term adjusted EPS growth target of 13%-16%, aggressive capital returns, and strategic realignment support a bullish outlook and potential for significant stock price appreciation by FY2030. Key risks include regulatory pressure on U.S. drug pricing, opioid litigation overhangs, execution risks in acquisitions and divestitures, and high customer concentration, which may cause volatility or corrections.
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity
Positive
Zacks Investment Research
6 days ago
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
Positive
Zacks Investment Research
7 days ago
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
Positive
CNBC Television
9 days ago
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
How to trade the health care break out
Positive
Zacks Investment Research
9 days ago
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?